Modality
mRNA
MOA
SGLT2i
Target
KRASG12C
Pathway
RAS/MAPK
PSP
Development Pipeline
Preclinical
Mar 2019
→ May 2026
PreclinicalCurrent
NCT04784887
1,972 pts·PSP
2019-03→2026-05·Not yet recruiting
1,972 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-05-262mo awayInterim· PSP
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
Preclinical
Not yet…
Catalysts
Interim
2026-05-26 · 2mo away
PSP
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04784887 | Preclinical | PSP | Not yet recr... | 1972 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| MRN-8225 | Moderna | Preclinical | TNFα |